Antidepressant Drug Data Boost Alkermes (ALKS), Cerecor (CERC); Proofpoint (PFPT) Surpasses Wall Street’s Expectations


Shares of Alkermes plc (Nasdaq:ALKS) soared more than 35% in after-hours trading Thursday as the company said that its investigational drug ALKS 5461 significantly reduced symptoms of depression in patients with major depressive disorder who didn’t respond well to other standard antidepressant therapies – in a late-stage pivotal study

ALKS stock finished the regular session in positive territory by 1.52% (or +$0.65) at $43.51 with a total volume of 2.72M shares traded, representing a large increase in activity versus its average volume (3m) of 772,640

Alkermes, which researches, develops, and commercializes innovative medicines for the treatment of central nervous system (CNS) diseases, has 151.56M Shares Outstanding and ALKS stock 52-week range is between $27.14 and $80.71 per share. At close on Thursday, the biopharmaceutical company had a Market Capitalization of $6.50B

Baltimore-based biopharmaceutical company Cerecor, Inc. (Nasdaq:CERC) – which is currently conducting an ongoing trial of its drug CERC-301 as an adjunctive treatment of major depressive disorder – saw its shares spike over 45% following Alkermes’ announcement



Proofpoint Inc. (Nasdaq:PFPT) shares climbed over 10% in the extended session Thursday after the company delivered in its financial results quarterly profit and revenue numbers well-above Wall Street analysts’ expectations and said that it will acquire FireLayers – an innovator in cloud security – for about $55M in cash and stock

For the third quarter 2016, the next-generation security and compliance company posted revenue of $99.8 million, a 44% increase year over year, and non-GAAP net income of $9.4 million, or $0.19 per diluted share, compared to a non-GAAP net loss of ($1.1) million, or ($0.03) per diluted share in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of $0.05 earnings per share on revenues of $94.26 million for the period

According to its business outlook for the fourth quarter 2016, Proofpoint expects revenue to be in a range of between $103.0 million and $105.0 million and non-GAAP net income ranging from $0.10 to $0.14 per diluted share, also exceeding the Capital IQ Consensus Estimate of $0.06 on revenues of $99.83 million for the next quarter

PFPT stock closed at $69.78, up $0.06 (or +0.09%), and 1.16M of its shares changed hands during the day

Proofpoint, which provides threat protection, incident response, regulatory compliance, archiving, governance, eDiscovery, and secure communication solutions, has 42.03M Shares Outstanding, Market Capitalization (intraday) of $2.88B and PFPT stock one-year range is from $35.56 to $80.68 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at